Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 244

1.

Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.

Travaglino F, Russo V, De Berardinis B, Numeroso F, Catania P, Cervellin G, Nigra SG, Geraci F, Bressan MA, Guerrini S, Cavazza M, Folli C, Monzani V, Battista S, Mengozzi G, Noto P, Carpinteri G, Semplicini A, Stella F, Ingrassia S, Moscatelli P, Giuntini P, Salerno G, Cardelli P, Di Somma S.

Am J Emerg Med. 2014 Apr;32(4):334-41. doi: 10.1016/j.ajem.2013.12.045. Epub 2014 Jan 3.

PMID:
24559907
2.

MR-proANP, MR-proADM, and PCT in Patients Presenting with Acute Dyspnea in a Medical Emergency Unit.

Heining L, Giesa C, Ewig S.

Lung. 2016 Apr;194(2):185-91. doi: 10.1007/s00408-015-9837-0. Epub 2016 Jan 9.

PMID:
26748496
3.

Evaluation of mid-regional pro-atrial natriuretic peptide, procalcitonin, and mid-regional pro-adrenomedullin for the diagnosis and risk stratification of dyspneic ED patients.

Cinar O, Cevik E, Acar A, Kaya C, Ardic S, Comert B, Yokusoglu M, Bilgi C, Meisner M, Madsen T.

Am J Emerg Med. 2012 Nov;30(9):1915-20. doi: 10.1016/j.ajem.2012.04.009. Epub 2012 Jun 27.

PMID:
22742951
4.

Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.

Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von Haehling S, Bergmann A, Morgenthaler NG, Anker SD.

J Am Coll Cardiol. 2010 May 11;55(19):2062-76. doi: 10.1016/j.jacc.2010.02.025.

5.

Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.

Maisel A, Mueller C, Nowak RM, Peacock WF, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di Somma S, Anand I, Ng LL, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Hartmann O, Morgenthaler NG, Anker SD.

J Am Coll Cardiol. 2011 Aug 30;58(10):1057-67. doi: 10.1016/j.jacc.2011.06.006.

6.

Utility of Procalcitonin (PCT) and Mid regional pro-Adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score.

Travaglino F, De Berardinis B, Magrini L, Bongiovanni C, Candelli M, Silveri NG, Legramante J, Galante A, Salerno G, Cardelli P, Di Somma S.

BMC Infect Dis. 2012 Aug 8;12:184.

7.

Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.

Shah RV, Truong QA, Gaggin HK, Pfannkuche J, Hartmann O, Januzzi JL Jr.

Eur Heart J. 2012 Sep;33(17):2197-205. doi: 10.1093/eurheartj/ehs136. Epub 2012 May 29.

8.

Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.

Pervez MO, Lyngbakken MN, Myhre PL, Brynildsen J, Langsjøen EC, Høiseth AD, Christensen G, Omland T, Røsjø H.

Clin Biochem. 2017 May;50(7-8):394-400. doi: 10.1016/j.clinbiochem.2016.12.010. Epub 2017 Jan 5.

PMID:
28065681
9.

Diagnostic and prognostic role of procalcitonin (PCT) and MR-pro-Adrenomedullin (MR-proADM) in bacterial infections.

Angeletti S, Spoto S, Fogolari M, Cortigiani M, Fioravanti M, De Florio L, Curcio B, Cavalieri D, Costantino S, Dicuonzo G.

APMIS. 2015 Sep;123(9):740-8. doi: 10.1111/apm.12406. Epub 2015 Jun 8.

PMID:
26058482
10.

Short-term mortality risk in emergency department acute heart failure.

Peacock WF, Nowak R, Christenson R, DiSomma S, Neath SX, Hartmann O, Mueller C, Ponikowski P, Möckel M, Hogan C, Wu AH, Richards M, Filippatos GS, Anand I, Ng LL, Daniels LB, Morgenthaler N, Anker SD, Maisel AS.

Acad Emerg Med. 2011 Sep;18(9):947-58. doi: 10.1111/j.1553-2712.2011.01150.x.

11.

Multiple biomarker strategy for improved diagnosis of acute heart failure in older patients presenting to the emergency department.

Bahrmann P, Bahrmann A, Hofner B, Christ M, Achenbach S, Sieber CC, Bertsch T.

Eur Heart J Acute Cardiovasc Care. 2015 Apr;4(2):137-47. doi: 10.1177/2048872614541904. Epub 2014 Jul 7.

PMID:
25002708
12.

Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia.

Courtais C, Kuster N, Dupuy AM, Folschveiller M, Jreige R, Bargnoux AS, Guiot J, Lefebvre S, Cristol JP, Sebbane M.

Am J Emerg Med. 2013 Jan;31(1):215-21. doi: 10.1016/j.ajem.2012.07.017. Epub 2012 Sep 20.

PMID:
23000327
13.

Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.

Krüger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T; German Competence Network for the Study of Community Acquired Pneumonia (CAPNETZ) Study Group.

Am J Respir Crit Care Med. 2010 Dec 1;182(11):1426-34. doi: 10.1164/rccm.201003-0415OC. Epub 2010 Jul 16.

PMID:
20639437
14.

Pro-adrenomedullin, pro-endothelin-1, procalcitonin, C-reactive protein and mortality risk in critically ill children: a prospective study.

Rey C, García-Hernández I, Concha A, Martínez-Camblor P, Botrán M, Medina A, Prieto B, López-Herce J.

Crit Care. 2013 Oct 16;17(5):R240. doi: 10.1186/cc13064.

15.

The effect of diabetes on the diagnostic and prognostic performance of mid-region pro-atrial natriuretic peptide and mid-region pro-adrenomedullin in patients with acute dyspnea.

Wu AH, Tabas J, Stein J, Potocki M, Mueller C, McCord J, Richards M, Hartmann O, Nowak R, Peacock WF, Ponikowski P, Moeckel M, Hogan C, Filippatos GS, Di Somma S, Anand I, Ng L, Neath SX, Christenson R, Morgenthaler NG, Anker SD, Maisel AS.

Biomarkers. 2012 Sep;17(6):490-7. doi: 10.3109/1354750X.2012.687014. Epub 2012 May 23.

PMID:
22616939
16.
17.

Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission.

Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, Lopez-Hoyos M, Santibañez M.

Intensive Care Med. 2013 Nov;39(11):1945-52. doi: 10.1007/s00134-013-3056-z. Epub 2013 Aug 16.

PMID:
23949703
18.

Usefulness of several biomarkers in the management of septic patients: C-reactive protein, procalcitonin, presepsin and mid-regional pro-adrenomedullin.

Enguix-Armada A, Escobar-Conesa R, García-De La Torre A, De La Torre-Prados MV.

Clin Chem Lab Med. 2016 Jan;54(1):163-8. doi: 10.1515/cclm-2015-0243.

PMID:
26083268
19.

Prognostic value of pro-adrenomedullin, procalcitonin and C-reactive protein in predicting outcome of febrile urinary tract infection.

van der Starre WE, Zunder SM, Vollaard AM, van Nieuwkoop C, Stalenhoef JE, Delfos NM, Van't Wout JW, Spelt IC, Blom JW, Leyten EM, Koster T, Ablij HC, van Dissel JT.

Clin Microbiol Infect. 2014 Oct;20(10):1048-54. doi: 10.1111/1469-0691.12645.

20.

Midregional pro-adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study.

Potocki M, Breidthardt T, Reichlin T, Morgenthaler NG, Bergmann A, Noveanu M, Schaub N, Uthoff H, Freidank H, Buser L, Bingisser R, Christ M, Mebazaa A, Mueller C.

Crit Care. 2009;13(4):R122. doi: 10.1186/cc7975. Epub 2009 Jul 23.

Supplemental Content

Support Center